Back

The therapeutic potential of relaxin for heart failure with preserved ejection fraction

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: HFpEF and HFmrEF: what’s new in treatment? Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Guy Salama

Upmc University Of Pittsburgh Medical Center, Pittsburgh (United States of America)

4 More presentations in this session

Presentation thumbnail
Trimetazidine in heart failure with preserved ejection fracton: a randomized, double-blind cross-over trial
Mr A. van de Bovenkamp (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trial
Associate Professor R. Wachter (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial
Professor J. Butler (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction
Doctor F. Lindberg (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
HFpEF and HFmrEF: what’s new in treatment?

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Daily Subcutaneous injections of Relaxin is a therapy for heart failure with preserved ejection fraction
thumbnail
Congress Presentation
RELAXIN-LA in worsening HFpEF
thumbnail
Congress Presentation
AZD3427, a novel relaxin receptor agonist and impact on renal perfusion in patients with heart failure with reduced ejection rraction: the phase 1b Re-Perfuse study design

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources